Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intravenous (IV) Eptinezumab in Paediatric Patients (6 to 17 Years) for the Preventive Treatment of Episodic Migraine

H. Lundbeck A/S

Summary

The main goal of this trial is to learn whether eptinezumab helps reduce the number of days with episodic migraine in pediatric participants.

Eligibility

Age range: 6–17 years
Sex: All
Healthy volunteers: No

Detailed criteria

Inclusion Criteria: * Diagnosis of migraine (with or without aura) according to the International Classification of Headache Disorders, 3rd edition (ICHD-3; in the opinion of the investigator) with history of migraine headaches of at least 6 months prior to the Screening Visit. * During the 28-day screening period, the participant (and their parent/caregiver, when applicable) must adequately complete the headache eDiary (≥23 of the 28 days) following the day of the Screening Visit. * During the 28-day screening period, the participant must have ≤14 headache days, of which at least 4 are migra…

Locations (62)

New England Institute for Clinical Research (NEICR) - Stamford
Stamford, Connecticut
Child Neurology Center (CNC) of Northwest Florida
Gulf Breeze, Florida
AGA Clinical Trials
Hialeah, Florida
University of South Florida (USF) - Tampa Campus
Tampa, Florida
Clinical Integrative Research Center of Atlanta (CIRCAtl)
Atlanta, Georgia
UK HealthCare-Kentucky Clinic
Lexington, Kentucky

Summary

Eligibility

Interventions

Locations (62)